News Releases

January 4, 2019
CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
In a release issued yesterday under the same headline by  Unum Therapeutics Inc.  (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical development to initiating preclinical development in the last paragraph.
January 3, 2019
Unum Therapeutics Announces Transition of Chief Financial Officer
CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that Christiana Stamoulis , President and Chief Financial Officer, will be stepping
January 3, 2019
Unum Therapeutics Announces 2019 Goals and Expected Milestones
- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - - Initial Data on ATTCK-34-01, Unum’s First Program in Solid Tumors, Expected in Second Half of 2019 - - First Development Candidate from BOXR Platform Advancing Toward Clinical Development - CAMBRIDGE, Mass. , Jan.
Displaying 21 - 23 of 23
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.